Latest News - Vertex Pharmaceuticals
Top Corporates Hub
Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
10.09.2026 04:17
Vertex Pharmaceuticals Incorporated (VRTX) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 4:30 PM EDTCompany ParticipantsConference Call...
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
10.09.2026 04:17
Vertex Pharmaceuticals Incorporated (VRTX) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 4:30 PM EDTCompany ParticipantsConference Call...
Vertex Pharmaceuticals: Solid Growth But Valuation Still Requires Flawless Execution
09.09.2026 05:59
Vertex Pharmaceuticals (VRTX) rated Hold: CF growth is solid but valuation, margin pressure and new-launch execution risks cap upside.
CRISPR Therapeutics: CASGEVY Validates The Platform, Strengthening The Acquisition Case
05.09.2026 06:10
CRISPR Therapeutics' current $5.6B market cap and $1.78B net cash position offer acquisition appeal. Click to know why CRSP is rated a Buy.
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now?
04.09.2026 18:50
They could both outperform the market over the medium term, but one appears to have a clear edge.
Vortex Energy Announces Plans for Ground Gravity Survey at the Robinsons River Salt Project
03.09.2026 13:00
Next Phase of Geophysical Work Advances Priority Targets Following August Technical StudyVANCOUVER, British Columbia, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce plans to undertake a targeted ground gravity survey at its 100%-owned Robinsons River Salt Project (the “Project”), located approximately 35 kilometres south of Stephenville, Newfoundland and Labrador. The survey has been selected as the Co
Vertex Pharmaceuticals: I Was Wrong About Its Near-Term Prospects (Rating Upgrade)
14.08.2026 09:40
Vertex Pharmaceuticals' revenue from its cystic fibrosis franchise grew 10% quarter-on-quarter. Click here to see why VRTX stock is a Buy.
Vertex (VRTX) Q2 2026 Earnings Call Transcript
11.08.2026 01:29
Revenue hit $3.3 billion with guidance raised on strong newer product growth.
Discover which S&P500 stocks are making waves on Monday.
10.08.2026 19:05
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.
SION Stock On Track For Worst Day Ever After 90% Drop — What’s Driving The Selloff?
10.08.2026 17:18
Sionna said on Monday that its mid-stage trial of SION-719 in 15 adults with cystic fibrosis already taking Vertex’s Trikafta failed to meet its main goal.
Why Sionna Therapeutics Stock Is Crashing 92% to a Record Low
10.08.2026 16:01
The biotech says its cystic fibrosis drug candidate missed the mark in a Phase 2a trial, though the news could be a boon to shares of Vertex Pharmaceuticals.
Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails
10.08.2026 15:55
Sionna's disappointing trial removes an immediate competitive threat to the franchise generating most of Vertex's revenue.
Vertex Pharmaceuticals (VRTX) Is Up 5.4% After Raising 2026 Revenue Guidance And Expanding Its Pipeline - Has The Bull Case Changed?
10.08.2026 15:14
Vertex Pharmaceuticals recently reported second-quarter 2026 results, with revenue rising to US$3,333.9 million and net income reaching US$1,099.8 million, and raised its full-year 2026 revenue guidance to US$13.10–US$13.20 billion. At the same time, a new collaboration with AbCellera on multispecific T‑cell engagers and a setback for a key cystic fibrosis competitor together highlight Vertex’s efforts to broaden its pipeline while easing pressure on its core franchise. We’ll now examine how...
Why Vertex Pharma Popped, As A Key Rival Plummeted 90%
10.08.2026 13:22
Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic fibrosis treatment.
Sionna cystic fibrosis drug fails key trial, removing threat to Vertex
10.08.2026 12:22
Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.
AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ...
06.08.2026 05:01
AbCellera Biologics Inc (ABCL) advances ABCL-635 with early phase 2 completion and secures over $110 million in new T-cell engager deals, despite a wider net loss and revenue decline.
Entrada Therapeutics Reports Second Quarter 2026 Financial Results
05.08.2026 11:00
-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- -- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 -- -- Company to report ELEVATE-45-201 Cohort 1 data in October 2026 -- -- ELEVATE-45-201 Cohort 2 dosing ongoing at the increased dose of 10 mg/kg with data expected in H1 2027 -- -- Vertex to report VX-670 Phase 1/2 data in people living with DM1 in H2 2026 -- BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc
CRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310
05.08.2026 10:09
CRISPR Therapeutics (CRSP) remains a Strong Buy, supported by robust CASGEVY sales growth and pipeline expansion.
Vertex (VRTX) Buys Crinetics To Push Beyond Cystic Fibrosis
04.08.2026 11:10
Vertex Pharmaceuticals (NasdaqGS:VRTX) has agreed to acquire Crinetics Pharmaceuticals in a deal expected to close in the third quarter of 2026. The transaction is designed to broaden Vertex's reach in biotech and add new disease areas beyond its core cystic fibrosis franchise. Investors are watching for the potential impact on Vertex's drug pipeline and competitive position as the companies work toward closing. Vertex Pharmaceuticals enters this deal with a sizeable track record in cystic...
Crinetics Pharmaceuticals (CRNX) Stock Looks Pricey As Buyout News Lands
04.08.2026 09:13
Crinetics Pharmaceuticals stock has delivered very strong gains over the past few years, yet the current valuation checks point to a market price that leans expensive rather than clearly cheap. Crinetics Pharmaceuticals has returned about 384% over the past 3 years, which puts recent enthusiasm for the stock firmly in focus for anyone thinking about upside from here. Vertex Pharmaceuticals' agreement to acquire Crinetics and the regulatory progress for atumelnant can support high...